Ambagon Therapeutics
Ambagon Therapeutics is a startup headquartered in Eindhoven, Netherlands, founded in 2020. It has raised at least $5.0m in outside funding, according to its filings with the US Securities and Exchange Commission (Form D), which puts it at the early stage.
Part of the 311 Institute Global Startups Directory (311institute.com). Last updated .
Funding
Ambagon Therapeutics has raised at least $5.0m in outside funding, according to its Form D filings with the US Securities and Exchange Commission. Form D figures are a minimum: not every round is filed.
R&D ecosystem
Ambagon Therapeutics sits inside the Randstad (Amsterdam, Delft, Leiden) R&D ecosystem in the Global R&D Labs Directory.
Related
- Innovation profile of Eindhoven
- Netherlands: economy and key statistics
- Global Investors Directory
- All 311 Indexes
Questions and answers
What does Ambagon Therapeutics do?
Ambagon Therapeutics is classed in biotechnology in its filings with the US Securities and Exchange Commission.
How much has Ambagon Therapeutics raised?
At least $5.0m, according to its Form D filings with the US Securities and Exchange Commission.
Where is Ambagon Therapeutics based?
Ambagon Therapeutics is headquartered in Eindhoven, Netherlands.
When was Ambagon Therapeutics founded?
Ambagon Therapeutics was founded in 2020.
Source record: SEC EDGAR (Form D filings).
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.